{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:23:26Z","timestamp":1784748206815,"version":"3.55.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Platelet-derived growth factor receptor A (PDGFRA) is a receptor tyrosine kinase that is activated by mutations in 10% of gastrointestinal stromal tumors (GISTs) and 55% to 70% of inflammatory fibroid polyps. <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>-mutant GISTs are usually epithelioid and occur predominantly in the stomach. Succinate dehydrogenase\u2013deficient GISTs also arise in the stomach and are usually epithelioid, as are some <jats:italic toggle=\"yes\">KIT<\/jats:italic>-mutant GISTs. Recently, avapritinib was approved to treat <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic> D842V-mutant GISTs, which do not respond to conventional targeted therapy. Here, we evaluate the utility of PDGFRA immunohistochemistry (IHC) to predict <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic> mutations to direct targeted therapy. PDGFRA IHC was performed at 1:3000 and 1:10,000 dilutions on a tissue microarray containing 153 GISTs (126 <jats:italic toggle=\"yes\">KIT<\/jats:italic>-mutant, 17 <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>-mutant, and 10 succinate dehydrogenase\u2013deficient). The \u201cpositive\u201d staining threshold was defined as 50% of neoplastic cells staining at moderate intensity. PDGFRA IHC was 75.0% and 80.9% specific for <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic> mutations at 1:3000 and 1:10,000 dilutions, respectively, and it was 100% sensitive at both. On the basis of its higher specificity, a 1:10,000 dilution was used to stain whole-tissue sections of GISTs and other gastric tumor types. Combining tissue microarray and whole-tissue data, PDGFRA IHC was 94.4% sensitive and 81.0% specific for <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>-mutant GIST among all 210 GISTs, and it was 84.1% specific among 149 GISTs with an epithelioid component. PDGFRA was positive in a subset of inflammatory fibroid polyps (15\/30; 50%), monophasic synovial sarcomas (5\/10; 50%), inflammatory myofibroblastic tumors (5\/10; 50%), and plexiform fibromyxomas (2\/8; 25%). It was negative in poorly differentiated adenocarcinoma (0\/20), diffuse large B-cell lymphoma (0\/10), glomus tumor (0\/10), gastrointestinal neuroectodermal tumor (0\/10), leiomyoma (0\/10), gastric schwannoma (0\/8), and gastroblastoma (0\/3). Among GISTs, PDGFRA IHC is highly sensitive and moderately specific for <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>-mutant tumors; it also can be positive in inflammatory fibroid polyp and some other mesenchymal tumor types. PDGFRA positivity could be used to triage epithelioid GISTs for <jats:italic toggle=\"yes\">PDGFRA<\/jats:italic> sequencing to determine optimal therapy.<\/jats:p>","DOI":"10.1097\/pas.0000000000001720","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T09:16:32Z","timestamp":1618650992000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["PDGFRA Immunohistochemistry Predicts PDGFRA Mutations in Gastrointestinal Stromal Tumors"],"prefix":"10.1097","volume":"46","author":[{"given":"David J.","family":"Papke","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"Forg\u00f3","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W.","family":"Charville","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.humpath.2006.07.002","article-title":"High incidence of microscopic gastrointestinal stromal tumors in the stomach","volume":"37","author":"Kawanowa","year":"2006","journal-title":"Hum Pathol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/01.pas.0000213307.05811.f0","article-title":"Minute gastric sclerosing stromal tumors (GIST Tumorlets) are common in adults and frequently show c-KIT mutations","volume":"31","author":"Agaimy","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.hoc.2013.07.003","article-title":"Gastrointestinal stromal tumors: molecular markers and genetic subtypes","volume":"27","author":"Barnett","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1097\/PAS.0b013e3182260752","article-title":"Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age","volume":"35","author":"Miettinen","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/PAS.0000000000000685","article-title":"Conventional risk stratification fails to predict progression of succinate dehydrogenase-deficient gastrointestinal stromal tumors: a clinicopathologic study of 76 cases","volume":"40","author":"Mason","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.pas.0000146010.92933.de","article-title":"Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up","volume":"29","author":"Miettinen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/PAS.0b013e3181d6150d","article-title":"Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types","volume":"34","author":"Gill","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2559.2012.04300.x","article-title":"Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study","volume":"61","author":"Doyle","year":"2012","journal-title":"Histopathology"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2559.2005.02061.x","article-title":"PDGFR\u03b1- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features","volume":"46","author":"Pauls","year":"2005","journal-title":"Histopathology"},{"key":"R13-20250608","first-page":"1839","article-title":"Value of epithelioid morphology and PDGFRA immunostaining pattern for prediction of PDGFRA mutated genotype in gastrointestinal stromal tumors (GISTs)","volume":"6","author":"Agaimy","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00292-009-1196-2","article-title":"Inflammatorische fibroide polypen sind echte neoplasien mit PDGFRA-Mutationen [Inflammatory fibroid polyps are true neoplasms with PDGFRA mutations]","volume":"30","author":"Schildhaus","year":"2009","journal-title":"Pathologe"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/modpathol.2009.62","article-title":"Gain-of-function PDGFRA mutations, earlier reported in gastrointestinal stromal tumors, are common in small intestinal inflammatory fibroid polyps. A study of 60 cases","volume":"22","author":"Lasota","year":"2009","journal-title":"Mod Pathol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2559.2012.04203.x","article-title":"Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization","volume":"61","author":"Huss","year":"2012","journal-title":"Histopathology"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/modpathol.2017.54","article-title":"Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model","volume":"30","author":"Demicco","year":"2017","journal-title":"Mod Pathol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2559.2008.02977.x","article-title":"Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours","volume":"53","author":"Lasota","year":"2008","journal-title":"Histopathology"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jamaoncol.2016.5751","article-title":"Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial","volume":"3","author":"Joensuu","year":"2017","journal-title":"JAMA Oncol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00000478-200407000-00007","article-title":"KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications","volume":"28","author":"Medeiros","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK","volume":"35","author":"Mari\u00f1o-Enr\u00edquez","year":"2011","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:05:49Z","timestamp":1749416749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001720","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,12]]}}}